A preponderance of siRNA therapeutic models targeting angiogenesis in HCC have targeted vascular endothelial growth factor (VEGF) expression (117) possibly because Sorafenib and its descendants, FDA approved antiangiogenic agents targeting VEGF, have had modest efficacy (126). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.